Issue 135 • October 2023

How pharma wants to break the efficacy ceiling in IBD

Despite major shifts in the inflammatory bowel disease landscape, most novel approaches remain in the earlier stages of development

Go to article: Home | How pharma wants to break the efficacy ceiling in IBDGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: UrsatecGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ControlantGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article:  Sensified.ioGo to article: In DepthGo to article: How pharma wants to break the efficacy ceiling in IBDGo to article: Subcutaneous drugs grant a new lease on life to checkpoint inhibitorsGo to article: Hope for the UK clinical trial landscape but it requires a lot of work Go to article: Novo Nordisk’s Wegovy to start being supplied by NHS in EnglandGo to article: Minimal impact expected for first ten drugs released for Medicare price negotiationGo to article: Q&A: Human touch remains critical for the patient experience in trialsGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue